| Previous close | 3.0900 |
| Open | 3.1000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 3.0100 - 3.1400 |
| 52-week range | 0.7140 - 3.5800 |
| Volume | |
| Avg. volume | 37,723 |
| Market cap | 16.28M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
NFL Biosciences: Recruitment completed for the PRECESTO study PRECESTO clinical trial to demonstrate the potential complementarity of NFL-101 with other smoking cessation treatments: 100% of volunteers recruited and initial results expected in the third quarter of 2023. NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that the final recruitments have been completed for the 34 volu
NFL Biosciences: 2022 full-year business and earnings update Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation: 100% of volunteers recruited. Initial results expected in the fourth quarter of 2023 Progress with the PRECESTO clinical trial to demonstrate the potential complementarity of NFL-101 with other smoking cessation treatments: final recruitment in the second quarter and initial results expected in the third quarter of 2023 Co-development agreement continuing
Changes in the governance of NFL Biosciences NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, and in particular NFL-101, its drug candidate for smoking cessation, announces the appointment of Ignacio Faus, current CEO, as Chairman of the Board of Directors. Appointment of Dr. Ignacio Faus as Chairman of the Board of Directors At its meeting on February 27, 2023, the Board of Directors of NFL Bi
NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study, which aims to demonstrate the complementarity of NFL-101 with other smoking cessation treatments NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical medicines for the treatment of addiction, announces the inclusion of the first volunteer in its PRECESTO clinical trial, designed to evaluate the complementarity of its NFL-101 treatment as a smoking cessation therapy
NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, and particularly NFL-101, its drug candidate for smoking cessation, is announcing that it has obtained financing for a total of €1.7 million, granted by Bpifrance and financed by the French government as part of the Programme d'Investissements d'Avenir. Ignacio
Tobacco addiction: NFL Biosciences collaborates with the CEA to study the mechanism of action of its drug candidate NFL-101 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependencies and addictions, announces the implementation of a study, with the French Alternative Energies and Atomic Energy Commission (CEA), on the mechanism of action of its drug candidate NFL-101. NFL-Biosciences will use the CEA's
Very successful capital increase for NFL Biosciences with over €3 million raised Strong success of the placement with professional investors with a diversified base of French and international investors for an amount of €2.45 million Exceptional participation of retail investors via the PrimaryBid platform with an offer oversubscribed nearly 3 times and almost 1,000 orders received, for a total amount of €1.6M, with €0.6M being allocated to the retail tranche1.Subscription price set at €2.23 per
NFL Biosciences launches a round of fundraising for approximately 2.5 million euros Capital increases as part of a global offer comprising an offer reserved for professional investors and a public offering for retail investors through the PrimaryBid platform.The PrimaryBid Offer will close on January 30 at 10pm and the Offer reserved for professional investors will close on January 31, 2023 before start of trading (subject to early closure).Price range of €2.08 to €2.35 per new share, representi
NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants recruited Main results expected by the end of 2023 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that is developing botanical drugs for the treatment of addictions, is announcing that the CESTO II Phase II/III clinical trial to assess the efficacy and safety of its NFL-101 smoking cessation treatment is progressing in l
NFL Biosciences: Financial calendar for the first half of 2023 NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, and particularly NFL-101, its drug candidate for smoking cessation, presents its financial communication calendar for the first half of 2023. Annual results 2022 (year ending December 31, 2022): Tuesday, April 25th 2023 before the opening of the stock marketAnnual General Shareholders
NFL Biosciences receives a joint grant from the French Government and the Occitanie Region for its PRECESTO clinical trial NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, and particularly NFL-101, its drug candidate for smoking cessation, is announcing that it has received a €200,000 grant, awarded jointly by the French Government and the Occitanie Region, for its PRECESTO clinical trial. NFL
NFL BIOSCIENCES: CLINICAL TRIAL APPROVED TO DEMONSTRATE THE COMPLEMENTARITY OF NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that its clinical trial to assess the complementarity of NFL-101 as a smoking cessation treatment with other smoking cessation treatments and particularly nicotine substitutes, has been approved by the Frenc
NFL BIOSCIENCES: NEW PATENT APPLICATION ASSOCIATING NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, announces it has submitted a new patent application to protect the administration of NFL-101 in association with other smoking cessation treatments, and particularly nicotine replacement therapies. The application was initially submitted in the Uni
NFL Biosciences: 2022 first-half business and earnings Phase II/III clinical trial for the drug candidate NFL-101 for smoking cessation continues to move forward, with the participation of eight clinical centers in France Intellectual property extended. NFL Biosciences patent registered in China and South Korea Partnership with Themis Medicare to develop NFL-101 in India Partnership with Athena Pharmaceutiques for the global development of NFL-301 Recruitment of a Finance Director NFL BIOSCIENCE
NFL BIOSCIENCES PARTNERS WITH THEMIS MEDICARE FOR THE DEVELOPMENT OF NFL-101 IN INDIA NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has entered into a partnership to develop NFL-101, the company’s drug candidate for smoking cessation, for the Indian market with Themis Medicare Ltd (NSE – Symbol: THEMISMED; BSE - Script code: 530199) a Pharmaceutical company headquartere
NFL BIOSCIENCESHALF-YEAR REVIEW OF THE LIQUIDITY AGREEMENT FOR H1 2022 Under the liquidity agreement concerning NFL Biosciences SA shares (FR0014003XT0 - ALNFL), entrusted to Invest Securities, the following resources were recorded in the liquidity account at June 30, 2022: 74,569 NFL BIOSCIENCES securities€12,560.02 of cash During the first half of 2022, the following trades were recorded: PURCHASES137,154 securities€192,820.70785 transactionsSALES111,050 securities€156,410.72759 transactions F
NFL BIOSCIENCES TO PRESENT AT THE H.C.WAINWRIGHT 1ST ANNUAL MENTAL HEALTH CONFERENCE NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that Ignacio Faus, Chief Executive Officer of NFL Biosciences, has been invited to present in the H.C. WAINWRIGHT 1st ANNUAL MENTAL HEALTH CONFERENCE on June 27 and 28, 2022. On this occasion, NFL Biosciences will have the opportunity to present its